No one seems to like drug companies these days, whether because their products are too expensive, their leaders are overpaid, or their marketing is sometimes less than legal.
“The sentiment out there is incredibly negative,” said Eric Emel of the advertising firm VML. “If it’s not Bernie Sanders, it’s Donald Trump. And if it’s not one of those two, it’s Heather Bresch or Martin Shkreli.”
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
